You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Armistice Capital | 0 | 1,614,000 | 0 | 1,614,000 | 1,614,000 | 9.9% |
| Armistice Capital Master Fund Ltd | 0 | 1,614,000 | 0 | 1,614,000 | 1,614,000 | 9.9% |
| Steven Boyd | 0 | 1,614,000 | 0 | 1,614,000 | 1,614,000 | 9.9% |
Follow Steven Boyd's Armistice Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 10 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.)*
| Eyegate Pharmaceuticals, Inc. |
| (Name of Issuer) |
| Common Stock, $0.01 par value per share |
| (Title of Class of Securities) |
| 30233M107 |
| (CUSIP Number) |
| June 9, 2017 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
__________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)
Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 10
